Skip to main content
. Author manuscript; available in PMC: 2022 Jul 23.
Published in final edited form as: ACS Appl Nano Mater. 2021 Jul 12;4(7):7343–7357. doi: 10.1021/acsanm.1c01320

Table 4.

MIC (μg/mL Based on Rifampicin) against E. coli ORN208a

entry samples wt % Rif MIC (μg/mL)
1 nonfluid liposomes (8:1 PC/Chol) >250/>250
2 nonfluid liposomes (8:1 PC/Chol)/Rif 8.7/8.7 12/6
3 nonfluid Man-glycoliposomes (8:1:0.8 PC/Chol/Man-DPPE)/Rif 6.6/6.6 8/4
4 nonfluid G7-liposomes (8:1:0.8 PC/Chol/G7-DPPE)/Rif 7.1/7.1 7/7
5 nonfluid G7-liposomes (8:1:0.8 PC/Chol/G7-DPPE) >250/>250
6 fluid liposomes (6:1 DPPC/DMPG)/Rif 7.9/7.9 6/3
7 fluid Man-glycoliposomes (6:1:0.6 DPPC/DMPG/Man-DPPE)/Rif 14/14 9/9
8 fluid G7-glycoliposomes (6:1:0.6 DPPC/DMPG/G7-DPPE)/Rif 16/16 2/2
9 rifampicin 6/6
a

Assays were repeated twice, and both results are presented.